Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Albendazole

FDA-approved product (tablet, oral), marketed as Albendazole, Albenza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Albendazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cysticercosis
  • Helminthiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzimidazole derivatives
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02CA03; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Albendazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Albendazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • East New Britain Province Monitoring & Evaluation

    NCT04124250 · start 2019-09-17

    Registered record
    Registry ID
    NCT04124250
    Conditions
    Lymphatic Filariasis Elimination by Mass Drug Administration; Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis; Acceptability of Mass Drug Administration for Lymphatic Filariasis
    Interventions
    Observational
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-17
    Completion
    2024-01-01
    Enrolment
    12,930

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis Elimination by Mass Drug Administration; Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis; Acceptability of Mass Drug Administration for Lymphatic Filariasis
    InterventionObservational
    PhaseNot recorded
    Registry statusCompleted

  • Urine Albendazole Levels for Coverage Assessment

    NCT04041427 · start 2019-07-17

    Registered record
    Registry ID
    NCT04041427
    Conditions
    Helminthiasis
    Interventions
    Albendazole Pill; High fat content diet; Moderate fat content die
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-07-17
    Completion
    2020-02-28
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelminthiasis
    InterventionAlbendazole Pill; High fat content diet; Moderate fat content die
    PhaseNot applicable
    Registry statusCompleted

  • Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old

    NCT03474276 · start 2018-01-31

    Registered record
    Registry ID
    NCT03474276
    Conditions
    Moderate Acute Malnutrition
    Interventions
    Azythromycin; Inuline and fructo-oligosaccharides; Albendazole; Fortified blend flour
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-31
    Completion
    2019-06-30
    Enrolment
    1,357

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Acute Malnutrition
    InterventionAzythromycin; Inuline and fructo-oligosaccharides; Albendazole; Fortified blend flour
    PhasePhase 3
    Registry statusCompleted

  • Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)

    NCT03014167 · start 2017-10-04

    Registered record
    Registry ID
    NCT03014167
    Conditions
    Helminthiasis; Filariasis
    Interventions
    Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-04
    Completion
    2024-07-02
    Enrolment
    357,716

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelminthiasis; Filariasis
    InterventionAlbendazole
    PhasePhase 3
    Registry statusCompleted

  • Twice Yearly Treatment for the Control of LF

    NCT03036059 · start 2017-05-19

    Registered record
    Registry ID
    NCT03036059
    Conditions
    Lymphatic Filariasis; Helminth Infection
    Interventions
    400 μg/kg Ivermectin + 400 mg Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-19
    Completion
    2019-12-08
    Enrolment
    1,462

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis; Helminth Infection
    Intervention400 μg/kg Ivermectin + 400 mg Albendazole
    PhasePhase 4
    Registry statusCompleted

  • Treatment Trial of Alveolar Echinococcosis

    NCT07182305 · start 2017-05-01

    Registered record
    Registry ID
    NCT07182305
    Conditions
    Alveolar Echinococcosis
    Interventions
    Efficacy of albendazole for early stage intervention of alveolar echinococcosis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2023-07-31
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlveolar Echinococcosis
    InterventionEfficacy of albendazole for early stage intervention of alveolar echinococcosis
    PhasePhase 2
    Registry statusCompleted

  • Effect of Routine Deworming on Weight of Children

    NCT03155035 · start 2017-03-07

    Registered record
    Registry ID
    NCT03155035
    Conditions
    Soil Transmitted Helminths
    Interventions
    Albendazole; Calcium 400 mg + Vitamin D 2.5 mcg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-03-07
    Completion
    2017-06-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoil Transmitted Helminths
    InterventionAlbendazole; Calcium 400 mg + Vitamin D 2.5 mcg
    PhaseNot applicable
    Registry statusCompleted

  • Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

    NCT02509481 · start 2015-06

    Registered record
    Registry ID
    NCT02509481
    Conditions
    Malaria; Lymphatic Filariasis
    Interventions
    Ivermectin; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2015-12
    Enrolment
    2,712

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Lymphatic Filariasis
    InterventionIvermectin; Albendazole
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin

    NCT02641210 · start 2015-01

    Registered record
    Registry ID
    NCT02641210
    Conditions
    Chronic Periodontitis
    Interventions
    Periodontal Treatment; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-10
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Periodontitis
    InterventionPeriodontal Treatment; Albendazole
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana

    NCT02078024 · start 2014-06

    Registered record
    Registry ID
    NCT02078024
    Conditions
    Onchocerciasis
    Interventions
    IVM plus ALB; IVM
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06
    Completion
    2018-06-25
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionIVM plus ALB; IVM
    PhasePhase 3
    Registry statusCompleted

  • Package of Interventions After Recovering From Moderate Acute Malnutrition

    NCT02351687 · start 2014-04

    Registered record
    Registry ID
    NCT02351687
    Conditions
    Malnutrition
    Interventions
    Lipid Nutrient Supplement; Sulfadoxine-pyrimethamine; Albendazole; Zinc; Insecticide-treated bednet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-06
    Enrolment
    1,499

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition
    InterventionLipid Nutrient Supplement; Sulfadoxine-pyrimethamine; Albendazole; Zinc +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

    NCT01748929 · start 2014-02-24

    Registered record
    Registry ID
    NCT01748929
    Conditions
    Intestinal Diseases, Parasitic
    Interventions
    Albendazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-02-24
    Completion
    2016-09-16
    Enrolment
    1,010

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Diseases, Parasitic
    InterventionAlbendazole; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis

    NCT01903057 · start 2014-02

    Registered record
    Registry ID
    NCT01903057
    Conditions
    Trachoma; Lymphatic Filariasis
    Interventions
    azithromycin; ivermectin; albendazole; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2014-02
    Completion
    2014-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrachoma; Lymphatic Filariasis
    Interventionazithromycin; ivermectin; albendazole; placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition

    NCT01395381 · start 2013-01

    Registered record
    Registry ID
    NCT01395381
    Conditions
    Kwashiorkor; Marasmus
    Interventions
    Placebo; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2013-01
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKwashiorkor; Marasmus
    InterventionPlacebo; Albendazole
    PhaseNot applicable
    Registry statusWithdrawn

  • Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone

    NCT01785680 · start 2013-01

    Registered record
    Registry ID
    NCT01785680
    Conditions
    Malnutrition
    Interventions
    Integrated Protocol; Current protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-11
    Enrolment
    1,957

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition
    InterventionIntegrated Protocol; Current protocol
    PhaseNot applicable
    Registry statusCompleted